David Moore (Dave) has served as the Chairman of the Board of Directors of Novasenta since mid-2023. Dave brings over 20 years of biopharma operational and executive management experience to Novasenta. He is currently the President of Novo Nordisk Inc and Executive Vice President of US Operations and Global Business Development. Previously at Novo Nordisk U.S., David also worked as a Senior Vice President, Commercial, where he led the successful transformation of the company’s commercial operating model into a purely integrated sales and marketing organization. He led the company through multiple new product launches, including one of the most successful launches in Type 2 diabetes to date, OZEMPIC.
Dave also worked in other leadership roles as a CEO at Roivant Sciences, a biopharmaceutical drug development company, focusing on infectious disease and as an Investment Partner with Gurnet Point Capital, a private equity firm focused in life sciences companies.
David holds a degree in biology from Towson University, an MBA from Lehigh University and completed the graduate program in population health and healthy policy at Thomas Jefferson University.